BGM — BGM Group Ltd.

Nasdaq · Health Care · Pharmaceuticals · CIK 1779578 · China
Last close
$0.25
Market Cap
$95.31M
52W High
$0.50
52W Low
$0.23
ADV30
199,056
Next earnings
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Sep 2025 433,814,485 9,819,570 41,916,992
Mar 2025 207,393,449 9,651,606 23,902,462
Sep 2024 53,003,728 9,817,254 8,910,379

Balance + Analyst (yfinance extras)

Retained Earnings
$-15,777,045
Inventory
$20,103,215
Receivables
$17,049,516
ST Investments
$994,895
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$37,919,424
EBITDA
$-11,118,474
Free Cash Flow
$3,499,949
Enterprise Value
$42,379,720
Total Cash
$10,814,465
Total Debt
$1,938,719
Shares Out
380,623,358
Trailing EPS
$-0.18
Book Value
$1.95
ROE
-9.3%
ROA
-3.2%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Sep 2025 37,919,425 -12,449,402 -19,941,242 433,814,485 41,916,992 -2,372,437
Sep 2024 25,097,951 -357,356 -1,442,830 53,003,728 8,910,379 544,238
Sep 2023 46,471,478 -2,417,724 -7,780,620 51,257,994 6,906,593 312,209
Sep 2022 64,855,025 2,515,720 1,076,693 64,526,617 9,563,081 12,654,188
Sep 2021

Peers — same industry

TickerNameMarket CapLastDaily %
ACRV Acrivon Therapeutics, Inc. $94.28M $2.20
FBIO Fortress Biotech, Inc. $97.72M $2.93
ZYBT Zhengye Biotechnology Holding Ltd $92.41M $1.95
HSTC HST Global, Inc. $91.93M $0.65
ALDX Aldeyra Therapeutics, Inc. $91.70M $1.52

News headlines (Yahoo Finance, 1h cache)

BGM Group Ltd. Receives NASDAQ Notice Related to Late Filing of Form 20-F
2026-02-26 21:15 · Yahoo
BGM Group Ltd. (BGM) Surges 35% as AI, Biopharma Transformation Gains Investor Attention
2025-10-01 17:41 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.